ClinicalTrials.gg
CompletedNCT04259346Updated Apr 8, 2022Results posted

A Study of Two Formulations of Ixekizumab in Healthy Participants

A Phase 1 interventional study of Ixekizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy male or female participants, with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study

Exclusion criteria

Exclusion Criteria:

  • Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study
  • Are allergic or hypersensitive to the study medicine
  • Had a vaccination with a within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study
  • Have any type of hepatitis, (HIV) infection, or other serious infection
  • Show evidence of active or latent tuberculosis (TB)
  • Presence of significant neuropsychiatric disorder or a recent history of depression
  • Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator, would pose an unacceptable risk to the participant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Ixekizumab (Reference)

    Approved formulation of 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).

    Drug: Ixekizumab

  • Experimental
    Ixekizumab (Test)

    Test formulation of 80 mg ixekizumab administered as a SC injection via AI.

    Drug: Ixekizumab

Interventions

  • Administered SC.

    Also known as: LY2439821

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab

    PK: Cmax of ixekizumab was evaluated

    Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose

  2. PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab

    Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.

    Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab

    Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.

    Time frame: Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose

07

Results

Posted Apr 8, 2022

Participant flow

Participant flow — Overall Study
Milestone80 Milligram (mg) Ixekizumab (Reference)80 mg Ixekizumab (Test)
Started126119
Received at least one dose of study drug126119
Completed122115
Not completed44
Withdrew: Lost to follow-up13
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject10
Withdrew: Adverse event11

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab

PK: Cmax of ixekizumab was evaluated

Time frame:
Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab
micrograms per milliliter (ug/mL)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab9.66 ± 339.97 ± 35
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab

Area under the plasma concentration versus time curve from time zero to the last measured concentration value (AUC\[0-tlast\]). AUC 0-tlast is equal to AUC (0-85) days where the last time point was 85 Days ± 3 Days.

Time frame:
Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · microgram*day/milliliter (ug*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab
microgram*day/milliliter (ug*day/mL)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)
PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Ixekizumab207 ± 31219 ± 28
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab

Area under the plasma concentration versus time curve from zero to infinity (AUC\[0-∞\]) of a single dose of Ixekizumab.

Time frame:
Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose
Reported as:
Geometric mean · ug*day/mL
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab
ug*day/mL80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Ixekizumab213 ± 33227 ± 30

Adverse events

Collected over Up to 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
80 mg Ixekizumab (Reference)0/126 (0%)0/126 (0%)36/126 (28.6%)
80 mg Ixekizumab (Test)0/119 (0%)0/119 (0%)14/119 (11.8%)
Most frequent other events
Most frequent other events
Event80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)
Injection site reactionGeneral disorders30/12611/119
HeadacheNervous system disorders9/1263/119

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)Total
Mean42.9 ± 12.846.8 ± 13.544.8 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)Total
Female6760127
Male5959118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)Total
Hispanic or Latino5846104
Not Hispanic or Latino6873141
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American321951
White9398191
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)80 mg Ixekizumab (Reference)80 mg Ixekizumab (Test)Total
United States126119245
08

Study locations

4 sites
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
  • Covance Clinical Research Inc
    Madison, Wisconsin 53704, United States
09

References and documents

Publications

  • Chabra S, Gill BJ, Gallo G, Zhu D, Pitou C, Payne CD, Accioly A, Puig L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. Adv Ther. 2022 Jun;39(6):2862-2872. doi: 10.1007/s12325-022-02126-0. Epub 2022 Apr 21. PubMed 35449322 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Feb 2021, 12 months.

Results were first posted in Apr 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2020
First posted
Feb 6, 2020
StartActual
Feb 5, 2020
Primary completionActual
Feb 19, 2021
CompletionActual
Feb 19, 2021
Results first posted
Apr 8, 2022
Last update
Apr 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04259346
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Feb 5, 2020
Primary completion
Feb 19, 2021
Completion
Feb 19, 2021
Results posted
Apr 8, 2022
Last update
Apr 8, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion